康柏西普眼用注射液治疗眼部新生血管性疾病出现不良反应的病例分析

发布时间：2018-05-28 13:28

本文选题：康柏西普眼用注射液 + 药物不良反应　；参考：《眼科新进展》2017年07期

【摘要】：目的统计分析全国2014年至2016年玻璃体内注射康柏西普眼用注射液的不良反应报告,以提高康柏西普眼用注射液临床应用的安全性。方法对2014年至2016年国家药品不良反应监测中心数据库中全国62家医疗机构使用康柏西普眼用注射液出现的248例不良反应病例进行统计分析。结果康柏西普眼用注射液临床使用中出现的药物不良反应主要累及眼部、心血管系统、骨骼肌系统及皮肤系统。药物不良反应主要发生于注射早期。248例不良反应的处理转归结果上报情况为痊愈126例,好转120例,未好转1例,1例预后不详,无死亡病例。结论应对康柏西普眼用注射液玻璃体内注射引起的眼内炎、视网膜脱离、玻璃体积血等严重不良反应加以重视,该药的严重不良反应及新的不良反应需作为上市后评价的关注要点。需加强对各医疗机构药物不良反应报告质量进行评估和管理。
[Abstract]:Objective to analyze the adverse reaction reports of intravitreous injection of Corbeseptide ophthalmic injection in China from 2014 to 2016 in order to improve the safety of clinical application. Methods from 2014 to 2016, 248 cases of adverse drug reactions (ADR) in 62 medical institutions in China were statistically analyzed in the database of the National Center for Monitoring adverse Drug reactions (ADRs). Results the adverse drug reactions occurred in the clinical use of Compactopril injection mainly involved the eye, cardiovascular system, skeletal muscle system and skin system. The main adverse drug reactions occurred in the early stage of injection. 248 cases of adverse reactions were reported to be cured in 126 cases, improved in 120 cases, and not improved in 1 case. The prognosis of 1 case was unknown and there was no death case. Conclusion serious adverse reactions such as endophthalmitis, retinal detachment and vitreous hemorrhage caused by intravitreous injection of Compactopril injection should be paid attention to. Serious adverse reactions and new adverse reactions of the drug need to be the focus of post-market evaluation. Evaluation and management of the quality of adverse drug reaction reports in various medical institutions should be strengthened.
【作者单位】：四川省医学科学院四川省人民医院城东病区眼科;成都市药物不良反应监测中心;四川省医学科学院四川省人民医院眼科;
【分类号】：R773

【相似文献】